Amphastar Pharmaceuticals AMPH US — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's us — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's US — revenue?
- Amphastar Pharmaceuticals (AMPH) reported US — revenue of $159.04M in Q1 2026.
- How has Amphastar Pharmaceuticals's US — revenue changed year-over-year?
- Amphastar Pharmaceuticals's US — revenue decreased by 2.2% year-over-year, from $162.59M to $159.04M.
- What is the long-term trend for Amphastar Pharmaceuticals's US — revenue?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's US — revenue has grown at a 12.9% compound annual growth rate (CAGR), from $419.87M to $681.42M.
- What does US — revenue mean?
- This metric represents the total gross sales generated from products sold within the United States geographic segment. It reflects the company's ability to capture market share and monetize its portfolio of injectable, inhalation, and intranasal products through domestic distribution channels. Growth in this figure indicates successful commercial execution and demand for the company's therapeutic offerings in the domestic market.